References
- Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004;45(9):1141–1149.
- Falsaperla R, Mauceri L, Pavone P, et al. Short-term neurodevelopmental outcome in term neonates treated with phenobarbital versus levetiracetam: a single-center experience. Behav Neurol. 2019;2019:1–8.
- Bialer M, Smith PE. Special issue: Phenobarbital: the Centenary – 10th European Congress on Epileptology, London – October 1, 2012. Introduction. Epilepsia. 2012;53 (Suppl 8):1–2.
- Willemsen AE, Lubberman FJ, Tol J, et al. Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors. Drug Discov Today. 2016;21(6):962–976.
- Hong T, Han S, Lee J, et al. Comparison of oral absorption models for pregabalin: usefulness of transit compartment model. Drug Des Dev Ther. 2016;10:3995–4003.
- Kohlmann P, Stillhart C, Kuentz M, et al. Investigating oral absorption of carbamazepine in pediatric populations. AAPS J. 2017;19(6):1864–1877.
- Kaneko S, Sato T, Suzuki K. The levels of anticonvulsants in breast milk. Br J Clin Pharmacol. 1979;7(6):624–627.
- Shareef S, Ali MN. Pharmacokinetics and optimal dosing of phenobarbital. Pediatr Neurol Briefs. 2018;32:7.
- Sun W, Wang J, Ding D, et al. Blood concentration, efficacy, and adverse events of phenobarbital: a prospective study in rural China. Epilepsy Behav. 2019;90:247–251.
- Jost J, Moyano LM, Auditeau E, et al. Interventional programs to improve therapeutic management of people with epilepsy in low- and middle-income countries. Epilepsy Behav. 2018;80:337–345.
- Duran-Alvarez JC, Becerril-Bravo E, Castro VS, et al. The analysis of a group of acidic pharmaceuticals, carbamazepine, and potential endocrine disrupting compounds in wastewater irrigated soils by gas chromatography-mass spectrometry. Talanta. 2009;78(3):1159–1166.